<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04699760</url>
  </required_header>
  <id_info>
    <org_study_id>H-4-2014-131</org_study_id>
    <nct_id>NCT04699760</nct_id>
  </id_info>
  <brief_title>The Effects of n-3 LCPUFAs in Patients With Colorectal Cancer</brief_title>
  <official_title>Single-blinded, Randomized, Controlled Trial About the Effects of n-3 LCPUFAs on Weight and Functional Status in Patients With Colorectal Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine the effects of n-3 PUFAs on weight, physical funktion&#xD;
      and quality of life in patients with colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary outcomes:&#xD;
&#xD;
        -  Weight&#xD;
&#xD;
        -  Physical function&#xD;
&#xD;
        -  Hand-grip strength&#xD;
&#xD;
      Secondary outcomes:&#xD;
&#xD;
        -  Quality of life&#xD;
&#xD;
        -  Mid-upperarm circumference&#xD;
&#xD;
        -  Incorporation of n-3 PUFAs into cell membranes&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight loss</measure>
    <time_frame>8 weeks</time_frame>
    <description>Difference in weight (kg) from inclusion to 8 week status</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>quality of Life score</measure>
    <time_frame>8 weeks</time_frame>
    <description>score - difference from inclusion to 8 week status (EORTC QLQ-C30 questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance status - common daily abilities</measure>
    <time_frame>8 weeks</time_frame>
    <description>combined scale - score - ADL</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Cancer Cachexia</condition>
  <condition>Side Effects</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Nutritional supplement without fish oil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fish oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nutritional supplement with fish oil</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish Oil</intervention_name>
    <description>8 weeks, 2.2 G EPA/day</description>
    <arm_group_label>Fish oil</arm_group_label>
    <other_name>Smart Fish - cancer cachexia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥18 years&#xD;
&#xD;
          -  Patients with diagnosed colorectal cancer with metastases treated with chemotherapy on&#xD;
             Rigshospitalet, Copenhagen&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt; 18 years&#xD;
&#xD;
          -  Patients in palliative care&#xD;
&#xD;
          -  patients with haemophilia&#xD;
&#xD;
          -  Patiens in treatment of anti-coagulation&#xD;
&#xD;
          -  Patients with genetic hyperkolesterolemia&#xD;
&#xD;
          -  Pre-dialytic patients (GFR&lt;15ml/min/1,73m2 eller kreatinin ≥500 mmol/L)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens R Andersen</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Departmen of Oncology, Rigshospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100 OE</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 23, 2020</study_first_submitted>
  <study_first_submitted_qc>January 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2021</study_first_posted>
  <last_update_submitted>January 6, 2021</last_update_submitted>
  <last_update_submitted_qc>January 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Jens Rikardt Andersen</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>nutrition</keyword>
  <keyword>fish oil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cachexia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

